MetLife (MET) Stock Forecast, Price Target & Predictions
MET Stock Forecast
MetLife stock forecast is as follows: an average price target of $87.46 (represents a 11.33% upside from MET’s last price of $78.56) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
MET Price Target
MET Analyst Ratings
MetLife Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 02, 2024 | John Barnidge | Piper Sandler | $92.00 | $81.78 | 12.50% | 17.11% |
Sep 04, 2024 | Alex Scott | Barclays | $91.00 | $77.52 | 17.39% | 15.84% |
Aug 01, 2024 | Joshua Shanker | Bank of America Securities | $96.00 | $76.85 | 24.92% | 22.20% |
Jul 10, 2024 | Bob Huang | Morgan Stanley | $83.00 | $69.92 | 18.71% | 5.65% |
May 22, 2024 | Kevin Heal | Argus Research | $80.00 | $73.15 | 9.36% | 1.83% |
May 06, 2024 | John Barnidge | Piper Sandler | $82.00 | $70.94 | 15.60% | 4.38% |
Mar 13, 2024 | Catherine Seifert | CFRA | $77.00 | $72.67 | 5.96% | -1.99% |
Jan 08, 2024 | Alex Scott | Goldman Sachs | $80.00 | $68.92 | 16.08% | 1.83% |
Sep 14, 2023 | Brett Linzey | Mizuho Securities | $145.00 | $63.79 | 127.31% | 84.57% |
Feb 02, 2023 | - | Morgan Stanley | $90.00 | $72.68 | 23.83% | 14.56% |
MetLife Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 2 | 8 |
Avg Price Target | - | $91.50 | $85.13 |
Last Closing Price | $78.56 | $78.56 | $78.56 |
Upside/Downside | -100.00% | 16.47% | 8.36% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 08, 2024 | Cowen & Co. | - | Buy | Initialise |
Oct 02, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Sep 27, 2024 | Jefferies | Buy | Buy | Hold |
Sep 26, 2024 | Evercore ISI | Outperform | Outperform | Hold |
Aug 12, 2024 | Wells Fargo | Overweight | Overweight | Hold |
Jul 23, 2024 | Citigroup | Buy | Buy | Hold |
Jul 18, 2024 | Jefferies | Buy | Buy | Hold |
Jul 10, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
May 06, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Apr 11, 2024 | Citigroup | Underperform | Underperform | Hold |
MetLife Financial Forecast
MetLife Revenue Forecast
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $15.87B | $16.62B | $15.39B | $16.32B | $22.27B | $15.56B | $1.16B | $19.17B | $15.23B | $15.86B | $14.28B | $19.71B | $15.44B |
Avg Forecast | $22.53B | $21.86B | $21.37B | $19.73B | $20.55B | $20.23B | $19.61B | $19.05B | $20.05B | $19.65B | $18.99B | $18.31B | $19.26B | $18.66B | $18.57B | $17.73B | $18.46B | $17.68B | $16.91B | $16.84B | $17.22B | $20.58B | $16.04B | $16.78B | $17.67B | $16.28B | $15.84B | $16.03B | $16.21B | $16.00B |
High Forecast | $23.77B | $23.06B | $22.55B | $20.82B | $21.68B | $21.34B | $20.68B | $20.09B | $21.15B | $20.73B | $20.03B | $18.80B | $20.90B | $18.70B | $18.57B | $17.73B | $19.42B | $18.62B | $17.84B | $17.76B | $18.16B | $20.58B | $16.04B | $16.78B | $17.67B | $16.28B | $15.84B | $16.03B | $16.21B | $16.00B |
Low Forecast | $21.51B | $20.86B | $20.40B | $18.84B | $19.62B | $19.31B | $18.71B | $18.18B | $19.14B | $18.76B | $18.12B | $17.78B | $18.07B | $18.62B | $18.57B | $17.73B | $17.72B | $16.71B | $16.14B | $16.07B | $16.43B | $20.58B | $16.04B | $16.78B | $17.67B | $16.28B | $15.84B | $16.03B | $16.21B | $16.00B |
# Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 4 | 5 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.90% | 0.98% | 0.91% | 0.95% | 1.08% | 0.97% | 0.07% | 1.08% | 0.94% | 1.00% | 0.89% | 1.22% | 0.96% |
MetLife EBITDA Forecast
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 4 | 5 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-78.00M | $-197.00M | $507.00M | $1.97B | $589.00M | $218.00M | $935.00M | $1.52B | $2.28B | $4.71B | $514.00M | $394.00M | $1.15B |
Avg Forecast | $1.53B | $1.49B | $1.46B | $1.34B | $1.40B | $1.38B | $1.33B | $1.30B | $1.37B | $1.34B | $1.29B | $1.25B | $1.31B | $1.27B | $1.26B | $1.11B | $1.26B | $1.20B | $1.15B | $874.54M | $965.93M | $1.40B | $1.09B | $691.33M | $1.20B | $1.11B | $1.08B | $317.81M | $1.10B | $1.09B |
High Forecast | $1.62B | $1.57B | $1.53B | $1.42B | $1.48B | $1.45B | $1.41B | $1.37B | $1.44B | $1.41B | $1.36B | $1.28B | $1.42B | $1.27B | $1.26B | $1.33B | $1.32B | $1.27B | $1.21B | $1.05B | $1.16B | $1.40B | $1.09B | $829.60M | $1.20B | $1.11B | $1.08B | $381.37M | $1.10B | $1.09B |
Low Forecast | $1.46B | $1.42B | $1.39B | $1.28B | $1.34B | $1.31B | $1.27B | $1.24B | $1.30B | $1.28B | $1.23B | $1.21B | $1.23B | $1.27B | $1.26B | $885.03M | $1.21B | $1.14B | $1.10B | $699.63M | $772.74M | $1.40B | $1.09B | $553.07M | $1.20B | $1.11B | $1.08B | $254.25M | $1.10B | $1.09B |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.06% | -0.17% | 0.58% | 2.04% | 0.42% | 0.20% | 1.35% | 1.27% | 2.05% | 4.37% | 1.62% | 0.36% | 1.05% |
MetLife Net Income Forecast
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 4 | 5 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $489.00M | $402.00M | $80.00M | $1.34B | $395.00M | $132.00M | $669.00M | $1.21B | $1.58B | $3.41B | $358.00M | $158.00M | $706.00M |
Avg Forecast | $2.23B | $2.20B | $2.14B | $1.88B | $1.98B | $1.96B | $1.91B | $1.69B | $1.80B | $1.77B | $1.75B | $1.52B | $1.61B | $1.53B | $1.48B | $791.56M | $1.32B | $1.37B | $1.34B | $625.74M | $763.74M | $843.50M | $1.04B | $494.65M | $1.05B | $1.24B | $1.20B | $221.35M | $1.09B | $1.15B |
High Forecast | $2.39B | $2.35B | $2.29B | $2.02B | $2.13B | $2.10B | $2.05B | $1.81B | $1.93B | $1.90B | $1.87B | $1.56B | $1.70B | $1.56B | $1.48B | $949.87M | $1.42B | $1.52B | $1.43B | $750.89M | $916.49M | $876.18M | $1.04B | $593.59M | $1.05B | $1.24B | $1.20B | $265.62M | $1.09B | $1.15B |
Low Forecast | $2.10B | $2.07B | $2.01B | $1.77B | $1.87B | $1.85B | $1.80B | $1.59B | $1.69B | $1.67B | $1.65B | $1.48B | $1.45B | $1.49B | $1.48B | $633.25M | $1.18B | $1.24B | $1.26B | $500.59M | $610.99M | $810.83M | $1.04B | $395.72M | $1.05B | $1.24B | $1.20B | $177.08M | $1.09B | $1.15B |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.36% | 0.30% | 0.13% | 1.76% | 0.47% | 0.13% | 1.35% | 1.15% | 1.28% | 2.83% | 1.62% | 0.15% | 0.61% |
MetLife SG&A Forecast
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 4 | 5 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.48B | $1.57B | $1.45B | - | $1.43B | $1.65B | $1.40B | $1.30B | $1.42B | $1.56B | $1.38B |
Avg Forecast | $1.97B | $1.91B | $1.87B | $1.73B | $1.80B | $1.77B | $1.72B | $1.67B | $1.76B | $1.72B | $1.66B | $1.60B | $1.69B | $1.63B | $1.63B | $1.70B | $1.62B | $1.55B | $1.48B | $1.34B | $1.04B | $1.80B | $1.40B | $1.06B | $1.55B | $1.43B | $1.39B | $877.37M | $1.42B | $1.40B |
High Forecast | $2.08B | $2.02B | $1.97B | $1.82B | $1.90B | $1.87B | $1.81B | $1.76B | $1.85B | $1.82B | $1.75B | $1.65B | $1.83B | $1.64B | $1.63B | $2.03B | $1.70B | $1.63B | $1.56B | $1.61B | $1.25B | $1.80B | $1.40B | $1.27B | $1.55B | $1.43B | $1.39B | $1.05B | $1.42B | $1.40B |
Low Forecast | $1.88B | $1.83B | $1.79B | $1.65B | $1.72B | $1.69B | $1.64B | $1.59B | $1.68B | $1.64B | $1.59B | $1.56B | $1.58B | $1.63B | $1.63B | $1.36B | $1.55B | $1.46B | $1.41B | $1.07B | $834.09M | $1.80B | $1.40B | $847.64M | $1.55B | $1.43B | $1.39B | $701.89M | $1.42B | $1.40B |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.10% | 1.50% | 0.81% | - | 1.35% | 1.06% | 0.98% | 0.94% | 1.62% | 1.10% | 0.99% |
MetLife EPS Forecast
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 4 | 5 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.56 | $0.48 | $0.02 | $1.69 | $0.42 | $0.13 | $0.74 | $1.44 | $1.78 | $3.85 | $0.33 | $0.14 | $0.70 |
Avg Forecast | $3.17 | $3.12 | $3.04 | $2.67 | $2.82 | $2.79 | $2.71 | $2.40 | $2.56 | $2.52 | $2.49 | $2.16 | $2.29 | $2.17 | $2.10 | $1.84 | $1.88 | $1.94 | $1.90 | $1.81 | $1.67 | $1.18 | $1.45 | $1.65 | $1.47 | $1.74 | $1.68 | $1.53 | $1.52 | $1.61 |
High Forecast | $3.40 | $3.35 | $3.25 | $2.87 | $3.02 | $2.99 | $2.91 | $2.57 | $2.74 | $2.70 | $2.66 | $2.22 | $2.42 | $2.22 | $2.10 | $1.84 | $2.02 | $2.16 | $2.04 | $1.94 | $1.79 | $1.23 | $1.45 | $1.65 | $1.47 | $1.74 | $1.68 | $1.53 | $1.52 | $1.61 |
Low Forecast | $2.98 | $2.94 | $2.86 | $2.52 | $2.65 | $2.62 | $2.55 | $2.26 | $2.41 | $2.37 | $2.34 | $2.10 | $2.06 | $2.12 | $2.10 | $1.84 | $1.68 | $1.77 | $1.79 | $1.71 | $1.57 | $1.13 | $1.45 | $1.65 | $1.47 | $1.74 | $1.68 | $1.53 | $1.52 | $1.61 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.29% | 0.25% | 0.01% | 1.01% | 0.36% | 0.09% | 0.45% | 0.98% | 1.02% | 2.29% | 0.22% | 0.09% | 0.43% |
MetLife Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
LNC | Lincoln National | $32.91 | $52.36 | 59.10% | Hold |
MET | MetLife | $78.56 | $87.46 | 11.33% | Buy |
UNM | Unum Group | $64.08 | $67.40 | 5.18% | Buy |
GL | Globe Life | $103.49 | $108.25 | 4.60% | Hold |
PRU | Prudential Financial | $120.66 | $116.00 | -3.86% | Buy |
JXN | Jackson Financial | $98.20 | $92.67 | -5.63% | Hold |
AFL | Aflac | $104.51 | $93.11 | -10.91% | Hold |
MFC | Manulife Financial | $29.70 | $25.86 | -12.93% | Buy |
CNO | CNO Financial Group | $35.75 | $31.00 | -13.29% | Hold |
MET Forecast FAQ
Is MetLife a good buy?
Yes, according to 11 Wall Street analysts, MetLife (MET) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 100.00% of MET's total ratings.
What is MET's price target?
MetLife (MET) average price target is $87.46 with a range of $74 to $145, implying a 11.33% from its last price of $78.56. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will MetLife stock go up soon?
According to Wall Street analysts' prediction for MET stock, the company can go up by 11.33% (from the last price of $78.56 to the average price target of $87.46), up by 84.57% based on the highest stock price target, and down by -5.80% based on the lowest stock price target.
Can MetLife stock reach $120?
MET's highest twelve months analyst stock price target of $145 supports the claim that MetLife can reach $120 in the near future.
What are MetLife's analysts' financial forecasts?
MetLife's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $79.44B (high $83.8B, low $75.82B), average EBITDA is $5.41B (high $5.71B, low $5.16B), average net income is $7.55B (high $8.09B, low $7.1B), average SG&A $6.95B (high $7.34B, low $6.64B), and average EPS is $10.73 (high $11.49, low $10.09). MET's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $85.5B (high $90.19B, low $81.6B), average EBITDA is $5.82B (high $6.14B, low $5.56B), average net income is $8.45B (high $9.05B, low $7.95B), average SG&A $7.49B (high $7.9B, low $7.14B), and average EPS is $12 (high $12.86, low $11.29).
Did the MET's actual financial results beat the analysts' financial forecasts?
Based on MetLife's last annual report (Dec 2022), the company's revenue was $69.9B, which missed the average analysts forecast of $70.61B by -1.01%. Apple's EBITDA was $3.78B, missing the average prediction of $4.15B by -8.97%. The company's net income was $2.54B, missing the average estimation of $3.14B by -19.10%. Apple's SG&A was $5.89B, beating the average forecast of $5.31B by 10.98%. Lastly, the company's EPS was $2.93, missing the average prediction of $5.95 by -50.73%. In terms of the last quarterly report (Sep 2023), MetLife's revenue was $15.87B, missing the average analysts' forecast of $17.68B by -10.26%. The company's EBITDA was $-78M, missing the average prediction of $1.2B by -106.48%. MetLife's net income was $489M, missing the average estimation of $1.37B by -64.26%. The company's SG&A was $0, missing the average forecast of $1.55B by -100.00%. Lastly, the company's EPS was $0.56, missing the average prediction of $1.94 by -71.19%